Cargando…
The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications
Hematological malignancies are treated with intensive high-dose chemotherapy, with or without radiation. This is followed by hematopoietic stem cell (HSC) transplantation (HSCT) to rescue or reconstitute hematopoiesis damaged by the anticancer therapy. Autologous HSC grafts may contain cancer cells...
Autores principales: | Tsang, Jovian J, Atkins, Harold L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918373/ https://www.ncbi.nlm.nih.gov/pubmed/27512666 http://dx.doi.org/10.2147/OV.S45525 |
Ejemplares similares
-
Ex Vivo Infection of Live Tissue with Oncolytic Viruses
por: Diallo, Jean-Simon, et al.
Publicado: (2011) -
Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances
por: Zheng, Meijun, et al.
Publicado: (2019) -
purgeR: inbreeding and purging in pedigreed populations
por: López-Cortegano, Eugenio
Publicado: (2021) -
Oncolytic Sendai virus-based virotherapy for cancer: recent advances
por: Saga, Kotaro, et al.
Publicado: (2015) -
Recent advances in oncolytic virus therapy for hepatocellular carcinoma
por: Zhu, Licheng, et al.
Publicado: (2023)